Biocon, a leading biotechnology company and its subsidiaries Biocon Pharma and Biocon Pharma Inc. (Biocon) have entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide).

 Shares of the company declined Rs 1.10, or 0.31%, to settle  at  Rs 355.60.  The total volume of shares traded  was  66.850 at  the BSE (Wednesday).  The scrip has touched an intra-day high of Rs 363 and low of Rs 353.80. The stock has touched its 52-week high of Rs 487.70 and 52-week low of Rs 327.75 on December 23, 2020 and August 23, 2021 respectively.